Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04360551 · ClinicalTrials.gov registry record · Phase 2
Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients
A Phase 2 study, sponsored by University of Hawaii.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT04360551 is a Phase 2 study that was terminated before completion, run by University of Hawaii. The registered enrollment target is 24 participants.
The verdict
NCT04360551, a Phase 2 study, was terminated before completion, sponsored by University of Hawaii.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will enroll 40 symptomatic outpatients tested positive for Coronavirus 2019 (COVID-19). Patients to be randomized 1:1 to Telmisartan (40 mg) vs placebo to be administered orally once daily x 21 days. Daily, the study patients will be asked to keep a record of the severity of their fever, dyspnea and fatigue and take their blood pressure (BP) and temperature. Study visits to occur on day 1 (entry), day 4, day 10 and day 21. Oro-pharyngeal swabs, and approximately 25 cc of blood will be collected at each study visit for safety labs and for the evaluation of the renin-angiotensin system (RAS) system and for various blood biomarkers of inflammation, coagulation and fibrosis.
Interventions
- DRUG Placebo
- DRUG Telmisartan 40mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2022-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04360551
The ClinicalTrials.gov registry entry for NCT04360551 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Hawaii, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04360551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04360551 about?
NCT04360551 is a clinical study titled "Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients". This study will enroll 40 symptomatic outpatients tested positive for Coronavirus 2019 (COVID-19). Patients to be randomized 1:1 to Telmisartan (40 mg) vs placebo to be administered orally once daily x 21 days. Daily, the study patients will be asked to keep a record of the severity of their fever, ...
What is the current status of trial NCT04360551?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-07-01. Estimated completion is 2022-04-26.
What interventions are being tested in trial NCT04360551?
The interventions under investigation include: Placebo (DRUG), Telmisartan 40mg (DRUG).
Who is sponsoring clinical trial NCT04360551?
This trial is sponsored by University of Hawaii, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.